J Korean Med Sci.  2020 Jun;35(24):e231. 10.3346/jkms.2020.35.e231.

A Case of Breakthrough COVID-19 during Hydroxychloroquine Maintenance

• Ahn BY
• Kang CK
• Seo JD
• Choe PG
• Song SH
• Park WB
• Park SW
• Kim NJ
• Oh Md

• KMID: 2503019
• DOI: http://doi.org/10.3346/jkms.2020.35.e231

Abstract

There have been controversies on the prophylactic effect of hydroxychloroquine against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). We describe a patient, 60-year old Korean woman, with coronavirus disease 2019 (COVID-19) who had been taking hydroxychloroquine for 6 months. Her serum and saliva concentrations of hydroxychloroquine were 280 μg/L and 4,890 μg/L, respectively. The present case raises concerns on hydroxychloroquine's role as a prophylactic agent for COVID-19.

Keyword

COVID-19; SARS-CoV-2; Hydroxychloroquine; Prophylaxis

Figure

• 

  Fig. 1 Clinical course of the patient who had a breakthrough COVID-19 during hydroxychloroquine maintenance.COVID-19 = coronavirus disease 2019, NP = nasopharyngeal, CRP = C-reactive protein, neg = negative.

• 

  Fig. 2 Chest computed tomography at April 10 shows bilateral, multiple, peribronchial patchy ground glass opacities.

Reference

1. Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020; 30(3):269–271. PMID: 32020029.

2. Yao X, Ye F, Zhang M, Cui C, Huang B, Niu P, et al. In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Clin Infect Dis. Forthcoming. 2020; DOI: 10.1093/cid/ciaa237.

3. Lee SH, Son H, Peck KR. Can post-exposure prophylaxis for COVID-19 be considered as an outbreak response strategy in long-term care hospitals? Int J Antimicrob Agents. 2020; 55(6):105988. PMID: 32305587.

4. Lahouati M, Mériglier E, Martin L, Bouchet S, Desclaux A, Bonnet F. COVID-19 infection also occurs in patients taking hydroxychloroquine. J Antimicrob Chemother. 2020; dkaa193.

5. Boulware DR, Pullen MF, Bangdiwala AS, Pastick KA, Lofgren SM, Okafor EC, et al. A randomized trial of hydroxychloroquine as postexposure prophylaxis for Covid-19. N Engl J Med. 2020; NEJMoa2016638.

6. Beigel JH, Tomashek KM, Dodd LE, Mehta AK, Zingman BS, Kalil AC, et al. Remdesivir for the treatment of Covid-19 - preliminary report. N Engl J Med. Forthcoming. 2020; DOI: 10.1056/NEJMoa2016638.

7. Efthimiadis A, Spanevello A, Hamid Q, Kelly MM, Linden M, Louis R, et al. Methods of sputum processing for cell counts, immunocytochemistry and in situ hybridisation. Eur Respir J Suppl. 2002; 37:19s–23s. PMID: 12361358.

8. Liu J, Cao R, Xu M, Wang X, Zhang H, Hu H, et al. Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro. Cell Discov. 2020; 6(1):16. PMID: 32194981.

9. White MR, Helmerhorst EJ, Ligtenberg A, Karpel M, Tecle T, Siqueira WL, et al. Multiple components contribute to ability of saliva to inhibit influenza viruses. Oral Microbiol Immunol. 2009; 24(1):18–24. PMID: 19121065.

10. Kang CK, Seong MW, Choi SJ, Kim TS, Choe PG, Song SH, et al. In vitro activity of lopinavir/ritonavir and hydroxychloroquine against SARS-CoV-2 at concentrations achievable by usual doses. Korean J Intern Med. Forthcoming. 2020; DOI: 10.3904/kjim.2020.157.

11. Geleris J, Sun Y, Platt J, Zucker J, Baldwin M, Hripcsak G, et al. Observational study of hydroxychloroquine in hospitalized patients with Covid-19. N Engl J Med. Forthcoming. 2020; DOI: 10.1056/NEJMoa2012410.

12. Chen J, Liu D, Liu L, Liu P, Xu Q, Xia L, et al. A pilot study of hydroxychloroquine in treatment of patients with common coronavirus disease-19 (COVID-19). J Zhejiang Univ. Forthcoming. 2020; DOI: 10.3785/j.issn.1008-9292.2020.03.03.

13. Jallouli M, Galicier L, Zahr N, Aumaître O, Francès C, Le Guern V, et al. Determinants of hydroxychloroquine blood concentration variations in systemic lupus erythematosus. Arthritis Rheumatol. 2015; 67(8):2176–2184. PMID: 25989906.